Log In
BCIQ
Print this Print this
 

ARQ 531

  Manage Alerts
Collapse Summary General Information
Company ArQule Inc.
DescriptionReversible inhibitor of the wild type and mutant (C481S) forms of Bruton's tyrosine kinase (BtK)
Molecular Target Bruton's tyrosine kinase (Btk)
Mechanism of ActionBruton's tyrosine kinase (Btk) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat ibrutinib resistant cancers
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today